Tell me this insider doesn't know something that is about too double his money, IMHO:
Incyte Corporation (INCY): INCY develops small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. Insiders currently hold 2.3 million or 1.8% of outstanding shares. During the past week, Director Baker, on behalf of Baker Bros. Life Science Capital, bought 2.5 million shares for $32.2 million. Mr. Baker has served as Director of Trimeris since 2004, and he is also a director at Neurogen Corp., Ardea Biosciences Inc. (RDEA) and Seattle Genetics Inc. (SGEN). He is also the managing member of Baker Bros. Advisors that manages the Baker Bros. Life Sciences Capital Fund that is focused solely on life science companies.